{"database":"biostudies-literature","file_versions":[],"scores":{"citationCount":0,"reanalysisCount":0,"viewCount":45,"searchCount":0},"additional":{"submitter":["Senthong V"],"funding":["NIDDK NIH HHS","NHLBI NIH HHS","National Institutes of Health"],"pagination":["106-116"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC5357587"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["14(2)"],"pubmed_abstract":["Introduction
Heart failure (HF) is a complex clinical syndrome with diverse risk factors and etiologies, differing underlying pathophysiology, and large phenotypic heterogeneity.Recent findings
Advances in imaging techniques coupled with clinical trials that targeted only in those with impaired left ventricular ejection fraction (LVEF) have largely shaped the current management strategy for HF that focuses predominantly in patients with systolic HF. In contrast, there are no effective treatments for HF with preserved ejection fraction (HFpEF). Instead of this \"one-size-fits-all\" approach to treatment, better precision to define HF phenotypic classifications may lead to more efficient and effective HF disease management.Conclusion
Integrating variables-including clinical variables, HF biomarkers, imaging, genotypes, metabolomics, and proteomics-can identify different pathophysiologies, lead to more precise phenotypic classification, and warrant investigation in future clinical trials."],"journal":["Current heart failure reports"],"pubmed_title":["Clinical Phenotyping of Heart Failure with Biomarkers: Current and Future Perspectives."],"pmcid":["PMC5357587"],"funding_grant_id":["P20 HL113452","R01 HL126827","R01 HL103931","R01HL126827","R01DK106000","R01 DK106000"],"pubmed_authors":["Senthong V","Tang WH","Kirsop JL"],"view_count":["45"],"additional_accession":[]},"is_claimable":false,"name":"Clinical Phenotyping of Heart Failure with Biomarkers: Current and Future Perspectives.","description":"Introduction
Heart failure (HF) is a complex clinical syndrome with diverse risk factors and etiologies, differing underlying pathophysiology, and large phenotypic heterogeneity.Recent findings
Advances in imaging techniques coupled with clinical trials that targeted only in those with impaired left ventricular ejection fraction (LVEF) have largely shaped the current management strategy for HF that focuses predominantly in patients with systolic HF. In contrast, there are no effective treatments for HF with preserved ejection fraction (HFpEF). Instead of this \"one-size-fits-all\" approach to treatment, better precision to define HF phenotypic classifications may lead to more efficient and effective HF disease management.Conclusion
Integrating variables-including clinical variables, HF biomarkers, imaging, genotypes, metabolomics, and proteomics-can identify different pathophysiologies, lead to more precise phenotypic classification, and warrant investigation in future clinical trials.","dates":{"release":"2017-01-01T00:00:00Z","publication":"2017 Apr","modification":"2024-02-15T10:54:49.949Z","creation":"2019-06-06T17:10:55Z"},"accession":"S-EPMC5357587","cross_references":{"pubmed":["28205040"],"doi":["10.1007/s11897-017-0321-4"]}}